Open in Screener

STTK

Shattuck Labs Inc

Sep 18 • 04:00PM ET

2.23

+0.29 14.95 %

Healthcare • Biotechnology • USA • NASD

Peers: KURA ADAP FATE DTIL AFMD ALXO HOOK ALDX IMTX

Index	-	P/E	-	EPS (ttm)	-1.21	Insider Own	28.51%	Shs Outstand	47.90M	Perf Week	12.63%
Market Cap	106.82M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	-	Shs Float	34.25M	Perf Month	116.50%
Enterprise Value	59.32M	PEG	-	EPS next Q	-0.14	Inst Own	72.01%	Short Float	2.80%	Perf Quarter	128.86%
Income	-61.51M	P/S	35.61	EPS this Y	52.48%	Inst Trans	49.10%	Short Ratio	0.41	Perf Half Y	87.39%
Sales	3.00M	P/B	1.87	EPS next Y	26.14%	ROA	-63.75%	Short Interest	0.96M	Perf YTD	84.30%
Book/sh	1.19	P/C	2.12	EPS next 5Y	21.86%	ROE	-73.39%	52W High	3.95 -43.54%	Perf Year	-39.57%
Cash/sh	1.05	P/FCF	-	EPS past 3/5Y	-11.56% -20.93%	ROIC	-104.20%	52W Low	0.69 222.18%	Perf 3Y	-30.09%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-42.45% -10.36%	Gross Margin	-25.39%	Volatility	14.44% 15.20%	Perf 5Y	-
Dividend TTM	-	EV/Sales	19.77	EPS Y/Y TTM	34.66%	Oper. Margin	-2165.73%	ATR (14)	0.21	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.25	Sales Y/Y TTM	-27.33%	Profit Margin	-2052.52%	RSI (14)	69.93	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	10.25	EPS Q/Q	42.42%	SMA20	49.50%	Beta	1.72	Target Price	3.00
Payout	-	Debt/Eq	0.05	Sales Q/Q	-100.00%	SMA50	103.81%	Rel Volume	0.19	Prev Close	1.94
Employees	44	LT Debt/Eq	0.04	Earnings	Aug 14 BMO	SMA200	103.24%	Avg Volume	2.31M	Price	2.23
IPO	Oct 09, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.04% -	Trades		Volume	438,611	Change	14.95%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-08-25	Initiated	Wedbush	Outperform	$4
Mar-17-25	Initiated	Leerink Partners	Outperform	$4
Oct-02-24	Downgrade	Needham	Buy → Hold
Oct-02-24	Downgrade	Citigroup	Buy → Neutral	$8 → $2
Oct-01-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-17-24	Downgrade	BTIG Research	Buy → Neutral
Aug-31-22	Initiated	BTIG Research	Buy	$12
Jun-01-22	Initiated	Citigroup	Buy	$13
May-02-22	Initiated	H.C. Wainwright	Buy	$28
Apr-14-21	Initiated	Berenberg	Buy	$47
Jan-11-21	Initiated	Evercore ISI	Outperform
Nov-03-20	Initiated	Needham	Buy	$34
Nov-03-20	Initiated	Cowen	Outperform
Nov-03-20	Initiated	Citigroup	Buy	$36

Show Previous Ratings

Sep-08-25 05:09PM	Shattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +21.29% +6.91%
Aug-26-25 06:30AM	Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors (GlobeNewswire)
Aug-21-25 10:17AM	Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease (GlobeNewswire) -11.42%
Aug-14-25 06:30AM	Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +6.13%
Aug-05-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +33.30%
06:30AM	Loading…
06:30AM	Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million (GlobeNewswire)
Jul-02-25 07:00AM	Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
May-01-25 04:20PM	Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +9.20% -7.81%
Apr-02-25 05:00PM	Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +16.28% -17.34%
Mar-27-25 07:00AM	Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-20-25 09:00AM	Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 (GlobeNewswire)
Feb-13-25 04:30PM	Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 (GlobeNewswire) +5.04% +6.40%
Feb-04-25 07:00AM	Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress (GlobeNewswire)
Jan-06-25 04:59PM	Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.22%
Jan-03-25 07:15AM	Shattuck Labs highlights upcoming key milestones in 2025 (TipRanks) +10.74%
07:00AM	Loading…
Jan-02-25 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025 (GlobeNewswire)
Nov-25-24 07:00AM	Shattuck Labs Announces Participation in Upcoming December Conferences (GlobeNewswire)
Nov-15-24 07:12AM	Shattuck Labs sees cash runway into 2027 (TipRanks) -9.85%
Nov-14-24 07:00AM	Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +12.30%
Oct-24-24 09:35AM	Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround (Zacks)
Oct-08-24 09:35AM	After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK) (Zacks) +11.50%
Oct-02-24 11:32AM	Shattuck Labs stock craters following pipeline and job cuts (Pharmaceutical Technology) -34.90%
06:57AM	Shattuck Labs Refocuses Strategy Amidst Restructuring and Cuts (TipRanks)
Oct-01-24 12:26PM	Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline (Benzinga) -44.99%
06:30AM	Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway (GlobeNewswire)
Aug-01-24 06:20PM	Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.28%
04:05PM	Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-30-24 05:00PM	Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-01-24 06:00AM	Shattuck Labs Announces Addition to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-18-24 06:25PM	Yigal Nochomovitz Just Trimmed Price Target for Shattuck Labs, Inc. (NASDAQ:STTK) (Insider Monkey) -7.83% -9.26%
10:48AM	Loading…
10:48AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
Jun-14-24 01:28PM	Shattuck (STTK) Announces Positive Interim Data on Cancer Drug (Zacks) -9.50%
06:00AM	Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Jun-10-24 07:30AM	Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML) (GlobeNewswire)
Jun-06-24 07:30AM	Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
May-21-24 09:35AM	After Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK) (Zacks)
May-14-24 04:15PM	Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire) -18.07%
May-07-24 12:00PM	What Makes Shattuck Labs (STTK) a New Buy Stock (Zacks)
09:55AM	Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect? (Zacks)
May-04-24 05:31AM	Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-02-24 09:58PM	STTK Stock Earnings: Shattuck Labs Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:25AM	Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:05AM	Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-09-24 04:05PM	Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) +8.44%
Apr-01-24 07:00AM	Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-04-24 07:00AM	Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors (GlobeNewswire)
Feb-29-24 04:05PM	Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +10.54%
Feb-26-24 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
Feb-14-24 05:06AM	Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins (PR Newswire) +6.03%
Feb-13-24 06:00AM	Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases (GlobeNewswire) -5.37%
Jan-08-24 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024 (GlobeNewswire) +14.94%
Jan-04-24 04:05PM	Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +12.14%
Dec-21-23 08:00AM	Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants (GlobeNewswire)
Dec-13-23 10:45AM	Why Is Shattuck Labs (STTK) Stock Up 93% Today? (InvestorPlace) +130.33%
06:00AM	Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Dec-05-23 04:15PM	Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023 (GlobeNewswire) +22.56%
Nov-14-23 09:00AM	Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +10.05%
Nov-13-23 08:52AM	Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 11:54PM	Q3 2023 Shattuck Labs Inc Earnings Call (Thomson Reuters StreetEvents) -23.21%
08:29AM	Shattuck Labs Inc (STTK) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
06:00AM	Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-06-23 09:28AM	Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023 (GlobeNewswire) +14.05%
Nov-02-23 09:01AM	Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +7.69%
Aug-10-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.64%
04:00PM	Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-06-23 10:14AM	Companies Like Shattuck Labs (NASDAQ:STTK) Could Be Quite Risky (Simply Wall St.) -7.07%
May-25-23 05:15PM	Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) -5.46%
May-09-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.56%
04:00PM	Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-03-23 07:00AM	Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-23 11:50AM	Great week for Shattuck Labs, Inc. (NASDAQ:STTK) institutional investors after losing 37% over the previous year (Simply Wall St.)
Mar-16-23 08:31AM	Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +8.93%
Mar-01-23 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
Feb-27-23 10:46PM	Shattuck Labs, Inc. (NASDAQ:STTK) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-23-23 04:30PM	Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-16-23 07:00AM	Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023 (GlobeNewswire)
Feb-09-23 06:01AM	Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-27-23 08:34AM	We Think Shattuck Labs (NASDAQ:STTK) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jan-09-23 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023 (GlobeNewswire)
Dec-13-22 06:51AM	Multiple insiders bought Shattuck Labs, Inc. (NASDAQ:STTK) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Dec-01-22 09:55AM	Shattuck Labs, Inc. (STTK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-11-22 05:51AM	Shattuck Labs Third Quarter 2022 Earnings: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021) (Simply Wall St.)
Nov-08-22 04:30PM	Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -6.75% -5.88%
Nov-07-22 08:00AM	Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-04-22 11:55AM	Investors in Shattuck Labs (NASDAQ:STTK) have unfortunately lost 86% over the last year (Simply Wall St.)
Nov-03-22 08:30AM	Shattuck Labs Announces Participation in Upcoming November Conferences (GlobeNewswire)
Nov-01-22 04:30PM	Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022 (GlobeNewswire) -8.66%
Oct-12-22 10:04AM	Owning 38% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK), (Simply Wall St.) +10.51%
Oct-05-22 04:30PM	Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12 (GlobeNewswire) +10.00%
Sep-01-22 04:15PM	Shattuck Labs Announces Participation in Upcoming September Conferences (GlobeNewswire)
Aug-20-22 08:41AM	We Think Shattuck Labs (NASDAQ:STTK) Needs To Drive Business Growth Carefully (Simply Wall St.)
Aug-11-22 07:00AM	Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-06-22 07:20AM	Quite a few insiders invested in Shattuck Labs, Inc. (NASDAQ:STTK) last year which is positive news for shareholders (Simply Wall St.) +20.93%
May-28-22 08:05AM	Shareholders in Shattuck Labs (NASDAQ:STTK) are in the red if they invested a year ago (Simply Wall St.)
May-13-22 08:50AM	Should You Buy Shattuck Labs (STTK) Ahead of Earnings? (Zacks)
May-12-22 07:00AM	Shattuck Labs Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) +8.28%
May-06-22 09:00AM	Why Earnings Season Could Be Great for Shattuck Labs (STTK) (Zacks) -7.28%
May-05-22 09:14AM	What Type Of Shareholders Own The Most Number of Shattuck Labs, Inc. (NASDAQ:STTK) Shares? (Simply Wall St.) -7.03%
Apr-08-22 04:55PM	Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)

Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. It focuses on developing a potential first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORBIMED ADVISORS LLC	Director	Aug 25 '25	Buy	0.87	6,306,127	5,471,826	5,255,106	Sep 02 09:52 PM
Ashiya Mona	Director	Aug 25 '25	Buy	0.87	6,306,127	5,471,826	5,255,106	Sep 02 09:50 PM
Redmile Group, LLC	Director	Dec 04 '24	Buy	1.25	133,371	166,714	5,539,724	Dec 06 09:00 PM
Redmile Group, LLC	Director	Dec 04 '24	Sale	1.25	133,371	166,714	5,406,353	Dec 06 09:00 PM
Redmile Group, LLC	Director, 10% Stockholder	Dec 04 '24	Proposed Sale	1.13	133,371	150,709		Dec 04 09:00 PM
Schreiber Taylor	Chief Executive Officer	Oct 07 '24	Buy	1.21	36,500	44,220	71,002	Oct 08 06:05 AM

Open in Screener

IRON

Disc Medicine Inc

Sep 18 • 04:00PM ET

62.63

+1.60 2.61 %

Healthcare • Biotechnology • USA • NASD

IRON Disc Medicine Inc daily Stock Chart

Peers: VRTX ALNY CRSP BEAM EDIT NTLA SRPT IONS BLUE SGMO

| Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO VHT DFAC

Index	RUT	P/E	-	EPS (ttm)	-4.48	Insider Own	33.98%	Shs Outstand	34.69M	Perf Week	3.88%
Market Cap	2.18B	Forward P/E	-	EPS next Y	-6.56	Insider Trans	-2.16%	Shs Float	22.95M	Perf Month	7.65%
Enterprise Value	1.56B	PEG	-	EPS next Q	-1.48	Inst Own	73.21%	Short Float	9.16%	Perf Quarter	25.03%
Income	-145.39M	P/S	-	EPS this Y	-39.12%	Inst Trans	6.58%	Short Ratio	6.02	Perf Half Y	16.54%
Sales	0.00M	P/B	3.54	EPS next Y	-19.04%	ROA	-24.74%	Short Interest	2.10M	Perf YTD	-1.21%
Book/sh	17.70	P/C	3.35	EPS next 5Y	-10.78%	ROE	-26.36%	52W High	68.73 -8.88%	Perf Year	31.35%
Cash/sh	18.70	P/FCF	-	EPS past 3/5Y	54.09% 38.12%	ROIC	-22.56%	52W Low	30.82 103.21%	Perf 3Y	328.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.77% 3.56%	Perf 5Y	-40.07%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-22.19%	Oper. Margin	-	ATR (14)	2.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	32.11	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	62.67	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	32.11	EPS Q/Q	-53.53%	SMA20	3.63%	Beta	0.78	Target Price	99.73
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	5.09%	Rel Volume	1.49	Prev Close	61.03
Employees	84	LT Debt/Eq	0.05	Earnings	Aug 07 BMO	SMA200	14.22%	Avg Volume	349.16K	Price	62.63
IPO	Aug 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-40.05% -	Trades		Volume	516,904	Change	2.61%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-25	Initiated	Truist	Buy	$86
Jul-03-25	Resumed	Morgan Stanley	Overweight	$85
Jun-11-25	Resumed	Raymond James	Strong Buy	$89
Feb-27-25	Initiated	TD Cowen	Buy
Nov-05-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$85
Nov-04-24	Upgrade	Raymond James	Outperform → Strong Buy	$66 → $110
Oct-23-24	Initiated	Jefferies	Buy	$89
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-22-24	Initiated	Wells Fargo	Overweight	$75
Apr-01-24	Downgrade	Raymond James	Strong Buy → Outperform	$40
Dec-19-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $65
Jun-09-23	Upgrade	Raymond James	Outperform → Strong Buy	$50 → $75
Jun-07-23	Initiated	H.C. Wainwright	Buy	$55
May-17-23	Initiated	Raymond James	Outperform	$50
Apr-28-23	Initiated	Cantor Fitzgerald	Overweight	$45
Apr-21-23	Initiated	Stifel	Buy	$37
Apr-20-23	Initiated	Morgan Stanley	Overweight	$37
Mar-23-23	Initiated	BMO Capital Markets	Outperform	$40
Feb-28-23	Initiated	SVB Securities	Outperform	$36

Show Previous Ratings

Aug-27-25 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-22-25 05:16PM	Rapid7, Residio Tech, and 4 More Stocks See Action From Activist Investors (Barrons.com)
Aug-07-25 08:30AM	Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-25 10:05AM	Disc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025 (Insider Monkey)
Jul-22-25 09:15AM	OrbiMed Promotes Mona Ashiya to General Partner (PR Newswire)
08:00AM	Loading…
Jul-21-25 08:00AM	Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025 (GlobeNewswire)
Jul-14-25 08:30AM	Disc Medicine Appoints Nadim Ahmed to its Board of Directors (GlobeNewswire)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT (Insider Monkey)
Jun-24-25 05:42PM	Leerink Partners Reiterates a Buy Rating on Disc Medicine (IRON) With an $85 Price Target (Insider Monkey) +6.42%
Jun-15-25 05:42AM	Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating (Insider Monkey)
Jun-12-25 07:30AM	Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress (GlobeNewswire)
Jun-11-25 09:45AM	Raymond James bullish on biotech firms on favorable valuation (Investing.com)
May-28-25 04:01PM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 09:30AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
May-13-25 08:00AM	Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
08:00AM	Loading…
May-07-25 08:00AM	Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-25 08:00AM	Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF) (GlobeNewswire)
Apr-09-25 07:13AM	Disc Medicine: Forging Ahead In Hematology (Seeking Alpha) +12.89%
Mar-26-25 09:39PM	Is Disc Medicine, Inc. (NASDAQ:IRON) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
Mar-21-25 06:35PM	Victorias Secret, Bitdeer, and More Stocks See Activist Action (Barrons.com)
Mar-14-25 12:00PM	All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy (Zacks)
Mar-03-25 09:55AM	Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know (Zacks)
Feb-27-25 08:00AM	Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-25 08:00AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-12-25 09:55AM	Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-23-25 08:28AM	Disc raises $225.5m as it eyes approval of rare skin disorder drug (Pharmaceutical Technology)
Jan-22-25 09:35PM	Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-21-25 04:01PM	Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
07:45AM	Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission (GlobeNewswire)
Jan-20-25 07:00PM	Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
04:00PM	Loading…
Jan-17-25 04:00PM	Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-10-25 09:00AM	Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025 (GlobeNewswire) -5.27%
Dec-09-24 12:00PM	Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-08-24 08:00PM	Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-24-24 06:10AM	Raymond James Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Nov-13-24 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 08:00AM	Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 10:38AM	Disc Medicine secures $200m financing to support trials (Clinical Trials Arena)
Nov-08-24 08:30AM	Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. (GlobeNewswire)
Nov-05-24 09:00AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +11.20%
Nov-04-24 01:44PM	Disc teases potential NDA for rare skin disorder drug (Pharmaceutical Technology) +23.59%
07:50AM	Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval (GlobeNewswire)
Nov-01-24 04:01PM	Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire) +5.15%
Oct-25-24 01:00PM	Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week (GlobeNewswire)
Oct-23-24 08:00AM	Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer (GlobeNewswire) -7.72%
Oct-11-24 08:00AM	Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week (GlobeNewswire)
Sep-19-24 08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffe, MD as Chief Regulatory Officer (GlobeNewswire)
08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caff , MD as Chief Regulatory Officer (GlobeNewswire)
Aug-30-24 08:00AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 08:00AM	Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jun-28-24 08:11PM	Bitfarms Technologies, Vestis, and More Stocks See Action From Activist Investors (Barrons.com)
Jun-14-24 08:03AM	Disc Medicine Announces Underwritten Offering of Common Stock (GlobeNewswire) +18.16%
07:30AM	Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire)
May-30-24 09:00AM	Disc Medicine to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 10:30AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire)
May-13-24 08:00AM	Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
May-11-24 05:31AM	Disc Medicine Inc (IRON) Reports Q1 2024 Earnings: A Detailed Financial Overview (GuruFocus.com)
May-09-24 01:54PM	IRON Stock Earnings: Disc Medicine Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-02-24 02:24PM	Disc Medicine (IRON) Down on Mixed Results From AURORA Study (Zacks) -6.36%
Apr-01-24 04:19PM	Disc Medicine Plummets After Placebo Effect Confounds Sunlight Sensitivity Study (Investor's Business Daily) -45.05%
08:00AM	Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Mar-23-24 05:31AM	Disc Medicine Inc (IRON) Reports Earnings: A Detailed Look at Fiscal Performance (GuruFocus.com)
Mar-21-24 08:00AM	Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.52%
Mar-06-24 04:30PM	Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire) -5.18%
Feb-26-24 08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer (GlobeNewswire)
Feb-20-24 08:30AM	Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease (GlobeNewswire)
Feb-09-24 09:00AM	Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera (GlobeNewswire)
Feb-07-24 08:00AM	Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer (GlobeNewswire)
Jan-03-24 05:00PM	Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 06:35PM	Peabody Energy, Janus International, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-20-23 04:30PM	Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board (GlobeNewswire)
Dec-15-23 03:01PM	Insider Sell Alert: Director William White Sells 33,511 Shares of Disc Medicine Inc (IRON) (GuruFocus.com)
Dec-11-23 08:30PM	Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
12:00PM	Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-08-23 07:06AM	Insider Sell Alert: CFO Joanne Bryce Sells 2,541 Shares of Disc Medicine Inc (IRON) (GuruFocus.com) +5.98%
Nov-14-23 04:44PM	Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin (GlobeNewswire)
Nov-13-23 09:55AM	How Much Upside is Left in Disc Medicine, Inc. (IRON)? Wall Street Analysts Think 38.17% (Zacks)
Nov-09-23 09:34AM	Disc Medicine Inc (IRON) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com)
08:30AM	Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-23 04:30PM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-02-23 09:00AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates (GlobeNewswire)
Oct-23-23 09:15AM	Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce (GlobeNewswire)
Oct-03-23 08:30AM	Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers (GlobeNewswire)
Sep-20-23 04:30PM	Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera (GlobeNewswire)
Aug-30-23 04:15PM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 11:20AM	Stock Screen Finds These Growth Stocks Outperforming The S&P 500 (Investor's Business Daily)
Aug-11-23 08:50AM	Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why (Zacks)
08:00AM	Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-27-23 09:00AM	Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA) (GlobeNewswire)
Jul-25-23 09:55AM	Here's Why Disc Medicine, Inc. (IRON) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-22-23 04:15PM	Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jun-20-23 07:33PM	Load Up, Says Raymond James About These 2 Strong Buy Stocks (TipRanks) +7.20%
Jun-13-23 10:39PM	Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jun-12-23 04:00PM	Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +6.92%
01:59AM	4 big analyst picks: Adobe a buy on AI hopes, says Wells Fargo (Investing.com)
Jun-09-23 04:13PM	Why Perfectly Rated Disc Medicine, With A 287% Move This Year, Just Put Up Another Big Gain (Investor's Business Daily) +15.76%
07:00AM	Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress (GlobeNewswire)
Jun-01-23 03:10PM	Why Shares of Disc Medicine Opco Climbed This Week (Motley Fool) +7.06%
May-31-23 04:00PM	Disc Medicine to Participate in the Jefferies Healthcare Conference (GlobeNewswire) +12.01%

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Quisel John D	Chief Executive Officer	Sep 09 '25	Option Exercise	1.01	10,000	10,100	171,828	Sep 11 06:00 PM
Bitterman Kevin	Director	Aug 22 '25	Sale	61.03	2,287	139,576	590,621	Aug 26 06:01 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 22 '25	Proposed Sale	59.75	2,287	136,648		Aug 22 04:29 PM
Atlas Venture Fund X, L.P.	Shareholder	Aug 22 '25	Proposed Sale	59.75	4,080	243,780		Aug 22 04:25 PM
Bitterman Kevin	Director	Aug 13 '25	Sale	61.15	24,962	1,526,426	600,120	Aug 15 07:23 PM
Bitterman Kevin	Director	Aug 14 '25	Sale	60.99	7,212	439,860	592,908	Aug 15 07:23 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 14 '25	Proposed Sale	61.10	7,212	440,653		Aug 14 04:24 PM
Atlas Venture Fund X, L.P.	Shareholder	Aug 14 '25	Proposed Sale	61.10	12,862	785,868		Aug 14 04:16 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 13 '25	Proposed Sale	59.03	24,962	1,473,507		Aug 13 04:26 PM
Atlas Venture Fund X, L.P.	Shareholder	Aug 13 '25	Proposed Sale	59.03	44,520	2,628,016		Aug 13 04:24 PM
Bitterman Kevin	Director	Aug 05 '25	Sale	60.95	395	24,075	625,082	Aug 07 05:00 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 05 '25	Proposed Sale	59.79	395	23,617		Aug 05 04:31 PM
Atlas Venture Fund X, L.P.	Shareholder	Aug 05 '25	Proposed Sale	59.79	705	42,152		Aug 05 04:24 PM
Bitterman Kevin	Director	Jul 30 '25	Sale	61.04	8,492	518,352	625,477	Aug 01 04:32 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 30 '25	Proposed Sale	59.80	8,492	507,822		Jul 30 04:18 PM
Atlas Venture Fund X, L.P.	Shareholder	Jul 30 '25	Proposed Sale	59.80	15,146	905,731		Jul 30 04:14 PM
Bitterman Kevin	Director	Jul 23 '25	Sale	60.97	29,837	1,819,162	647,002	Jul 25 05:22 PM
Bitterman Kevin	Director	Jul 24 '25	Sale	61.17	13,033	797,229	633,969	Jul 25 05:22 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 24 '25	Proposed Sale	60.94	13,033	794,231		Jul 24 04:27 PM
Atlas Venture Fund X, L.P.	Shareholder	Jul 24 '25	Proposed Sale	60.94	23,245	1,416,550		Jul 24 04:25 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 23 '25	Proposed Sale	60.74	29,837	1,812,299		Jul 23 04:30 PM
Atlas Venture Fund X, L.P.	Shareholder	Jul 23 '25	Proposed Sale	60.74	53,215	3,232,279		Jul 23 04:25 PM
Bitterman Kevin	Director	Jul 18 '25	Sale	61.13	664	40,590	676,839	Jul 22 04:44 PM
Franchi Jean M.	Chief Financial Officer	Jul 17 '25	Sale	59.00	2,031	119,829	63,499	Jul 18 04:51 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 18 '25	Proposed Sale	57.79	664	38,373		Jul 18 04:33 PM
Atlas Venture Fund X, L.P.	Shareholder	Jul 18 '25	Proposed Sale	57.79	1,184	68,423		Jul 18 04:31 PM
JEAN FRANCHI	Officer	Jul 17 '25	Proposed Sale	57.34	2,031	116,458		Jul 17 04:20 PM
Franchi Jean M.	Chief Financial Officer	Jul 10 '25	Sale	57.50	2,000	115,000	65,530	Jul 14 09:36 PM
Quisel John D	Chief Executive Officer	Jul 09 '25	Option Exercise	9.86	34,800	343,128	196,628	Jul 11 04:48 PM
Quisel John D	Chief Executive Officer	Jul 09 '25	Sale	55.33	34,800	1,925,525	161,828	Jul 11 04:48 PM
JEAN FRANCHI	Officer	Jul 10 '25	Proposed Sale	55.86	2,000	111,720		Jul 10 04:34 PM
JOHN QUISEL	Director	Jul 09 '25	Proposed Sale	52.97	34,800	1,843,356		Jul 09 04:17 PM
Quisel John D	Chief Executive Officer	Jul 03 '25	Option Exercise	9.86	5,200	51,272	167,028	Jul 08 08:19 PM
Quisel John D	Chief Executive Officer	Jul 03 '25	Sale	55.09	5,200	286,454	161,828	Jul 08 08:19 PM
JOHN QUISEL	Director	Jul 03 '25	Proposed Sale	53.17	5,200	276,484		Jul 03 01:30 PM
Savage William Jacob	Chief Medical Officer	Jun 27 '25	Option Exercise	9.86	32,070	316,210	88,795	Jul 01 04:50 PM
Franchi Jean M.	Chief Financial Officer	Jun 16 '25	Sale	52.26	2,000	104,519	67,530	Jun 18 05:18 PM
JEAN FRANCHI	Officer	Jun 16 '25	Proposed Sale	53.71	2,000	107,420		Jun 16 04:22 PM
Savage William Jacob	Chief Medical Officer	Jun 06 '25	Sale	50.00	2,996	149,800	56,725	Jun 09 08:49 PM
WILLIAM SAVAGE	Officer	Jun 06 '25	Proposed Sale	48.01	2,996	143,838		Jun 06 04:25 PM
Savage William Jacob	Chief Medical Officer	May 20 '25	Sale	50.04	6,677	334,128	59,721	May 22 06:31 PM
Savage William Jacob	Chief Medical Officer	May 02 '25	Sale	50.17	2,100	105,367	66,398	May 06 08:53 PM
WILLIAM SAVAGE	Officer	May 02 '25	Proposed Sale	49.68	8,777	436,041		May 02 04:22 PM
Quisel John D	Chief Executive Officer	Apr 07 '25	Option Exercise	1.01	7,000	7,070	161,828	Apr 08 08:22 PM
Ashiya Mona	Director	Mar 24 '25	Sale	54.11	5,738	310,483	186,541	Mar 26 07:08 PM
ORBIMED ADVISORS LLC	Director	Mar 24 '25	Sale	54.11	5,738	310,483	186,541	Mar 26 07:00 PM
Ashiya Mona	Director	Mar 19 '25	Sale	54.02	39,656	2,142,217	188,981	Mar 21 08:03 PM
Ashiya Mona	Director	Mar 21 '25	Sale	54.00	10,011	540,594	187,297	Mar 21 08:03 PM
Ashiya Mona	Director	Mar 20 '25	Sale	54.01	2,762	149,176	188,617	Mar 21 08:03 PM
ORBIMED ADVISORS LLC	Director	Mar 19 '25	Sale	54.02	39,656	2,142,217	188,981	Mar 21 08:00 PM
ORBIMED ADVISORS LLC	Director	Mar 21 '25	Sale	54.00	10,011	540,594	187,297	Mar 21 08:00 PM
ORBIMED ADVISORS LLC	Director	Mar 20 '25	Sale	54.01	2,762	149,176	188,617	Mar 21 08:00 PM
Ashiya Mona	Director	Mar 10 '25	Sale	54.29	202,146	10,974,794	208,742	Mar 12 09:36 PM
Ashiya Mona	Director	Mar 12 '25	Sale	54.45	83,182	4,529,507	194,209	Mar 12 09:36 PM
Ashiya Mona	Director	Mar 11 '25	Sale	54.01	27,056	1,461,295	205,175	Mar 12 09:36 PM
ORBIMED ADVISORS LLC	Director	Mar 10 '25	Sale	54.29	202,146	10,974,794	208,742	Mar 12 09:34 PM
ORBIMED ADVISORS LLC	Director	Mar 12 '25	Sale	54.45	83,182	4,529,507	194,209	Mar 12 09:34 PM
ORBIMED ADVISORS LLC	Director	Mar 11 '25	Sale	54.01	27,056	1,461,295	205,175	Mar 12 09:34 PM
OrbiMed Genesis Master Fund, L	Director	Mar 10 '25	Proposed Sale	55.67	74,800	4,164,116		Mar 10 06:46 PM
OrbiMed Private Investments VI	Director	Mar 10 '25	Proposed Sale	55.67	193,400	10,766,578		Mar 10 06:45 PM
OrbiMed Private Investments VI	Director	Mar 10 '25	Proposed Sale	55.67	299,200	16,656,464		Mar 10 06:44 PM
Stephenson Pamela	Chief Commercial Officer	Feb 18 '25	Sale	54.58	3,137	171,217	69,529	Feb 20 07:38 PM
Khara Rahul	Chief Legal Officer	Feb 18 '25	Sale	54.58	1,161	63,367	37,583	Feb 20 07:36 PM
Savage William Jacob	Chief Medical Officer	Feb 18 '25	Sale	54.58	1,638	89,402	68,498	Feb 20 07:33 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Feb 18 '25	Sale	54.58	1,610	87,874	40,555	Feb 20 07:31 PM
Franchi Jean M.	Chief Financial Officer	Feb 18 '25	Sale	54.58	3,136	171,163	69,530	Feb 20 07:29 PM
Quisel John D	Chief Executive Officer	Feb 18 '25	Sale	54.58	5,574	304,229	154,828	Feb 20 07:27 PM
Savage William Jacob	Chief Medical Officer	Feb 03 '25	Option Exercise	2.65	5,731	15,187	46,136	Feb 12 06:33 PM
Atlas Venture Fund X, L.P.	Shareholder	Feb 05 '25	Proposed Sale	54.32	112,211	6,095,302		Feb 05 04:05 PM
Khara Rahul	Chief Legal Officer	Feb 03 '25	Option Exercise	14.69	7,500	110,175	21,535	Feb 04 05:18 PM
Khara Rahul	Chief Legal Officer	Feb 03 '25	Sale	55.54	7,500	416,574	14,035	Feb 04 05:18 PM
Atlas Venture Fund X, L.P.	Shareholder	Feb 04 '25	Proposed Sale	54.99	6,350	349,186		Feb 04 05:14 PM
Atlas Venture Fund X, L.P.	Shareholder	Feb 03 '25	Proposed Sale	55.80	6,439	359,296		Feb 03 04:28 PM
Khara Rahul	Chief Legal Officer	Jan 02 '25	Option Exercise	14.69	7,500	110,175	21,535	Jan 06 05:56 PM
Khara Rahul	Chief Legal Officer	Jan 02 '25	Sale	62.75	7,500	470,658	14,035	Jan 06 05:56 PM
Quisel John D	Chief Executive Officer	Dec 30 '24	Option Exercise	9.86	13,012	128,298	85,077	Jan 02 07:13 PM
Quisel John D	Chief Executive Officer	Dec 31 '24	Option Exercise	1.01	10,000	10,100	82,065	Jan 02 07:13 PM
Quisel John D	Chief Executive Officer	Dec 30 '24	Sale	61.95	13,012	806,058	72,065	Jan 02 07:13 PM
RAHUL KHARA	Officer	Jan 02 '25	Proposed Sale	63.40	15,000	951,000		Jan 02 04:20 PM
JOHN QUISEL	Director	Dec 30 '24	Proposed Sale	64.12	13,012	834,329		Dec 30 04:11 PM
Quisel John D	Chief Executive Officer	Dec 23 '24	Option Exercise	2.65	19,820	52,523	91,885	Dec 26 05:18 PM
Quisel John D	Chief Executive Officer	Dec 23 '24	Sale	63.14	19,820	1,251,357	72,065	Dec 26 05:18 PM
JOHN QUISEL	Director	Dec 23 '24	Proposed Sale	64.50	19,820	1,278,390		Dec 23 04:21 PM
Quisel John D	Chief Executive Officer	Dec 16 '24	Option Exercise	1.01	12,791	12,919	84,856	Dec 18 07:41 PM
Quisel John D	Chief Executive Officer	Dec 16 '24	Sale	66.01	12,791	844,314	72,065	Dec 18 07:41 PM
JOHN QUISEL	Director	Dec 16 '24	Proposed Sale	64.89	12,791	830,008		Dec 16 04:39 PM
White William Richard	Director	Dec 02 '24	Option Exercise	3.39	1,957	6,635	1,957	Dec 04 07:43 PM
White William Richard	Director	Dec 02 '24	Sale	64.63	1,957	126,490	0	Dec 04 07:43 PM
Savage William Jacob	Chief Medical Officer	Nov 25 '24	Option Exercise	12.15	14,183	172,313	54,588	Nov 26 08:03 PM
Savage William Jacob	Chief Medical Officer	Nov 25 '24	Sale	65.45	14,183	928,326	40,405	Nov 26 08:03 PM
WILLIAM SAVAGE	Officer	Nov 25 '24	Proposed Sale	64.96	14,183	921,328		Nov 25 04:46 PM
Savage William Jacob	Chief Medical Officer	Nov 15 '24	Option Exercise	9.86	9,158	90,298	49,563	Nov 19 06:46 PM
Savage William Jacob	Chief Medical Officer	Nov 15 '24	Sale	59.64	9,158	546,153	40,405	Nov 19 06:46 PM
WILLIAM SAVAGE	Officer	Nov 15 '24	Proposed Sale	60.67	9,158	555,616		Nov 15 04:39 PM
White William Richard	Director	Nov 04 '24	Option Exercise	45.69	7,136	326,044	7,136	Nov 05 07:16 PM
White William Richard	Director	Nov 01 '24	Option Exercise	9.86	201	1,982	201	Nov 05 07:16 PM
White William Richard	Director	Nov 04 '24	Sale	58.61	7,136	418,206	0	Nov 05 07:16 PM
White William Richard	Director	Nov 01 '24	Sale	46.37	201	9,319	0	Nov 05 07:16 PM
White William Richard	Director	Nov 04 '24	Proposed Sale	47.13	7,136	336,320		Nov 04 04:07 PM
White William Richard	Director	Nov 01 '24	Proposed Sale	44.82	2,158	96,722		Nov 01 04:19 PM

STTK

Shattuck Labs Inc

IRON

Disc Medicine Inc

Upgrade your FINVIZ experience